Impel NeuroPharma has named Leonard S. Paolillo as Chief Commercial Officer and Gerald F. Penn as VP, Market Access and Trade in anticipation of the launch of Trudhesa intranasal dihydroergotamine mesylate (DHE) for the treatment of migraine headaches if approved by the FDA. Impel submitted an NDA for Trudhesa (INP104)in November 2020, and the FDA has set a PDUFA goal date of September 6, 2021.
Paolillo was most recently Executive VP and Chief Commercial Officer at Kyowa Kirin Inc. and previously held various sales positions at Warner Chilcott Pharmaceuticals. Penn was most recently VP of Market Access and Trade at Esperion Therapeutics and previously worked for a number of companies, including Aralez Pharmaceuticals, Kaleo, and Auxilium Pharmaceuticals. The company noted that it also recently appointed another veteran of Aralez and Auxilium, Rigo Canal, as VP, Commercial Operations and Analytics.
Impel NeuroPharma Chairman and CEO Adrian Adams said, “I am delighted to welcome these industry professionals to our team at this exciting time in Impel NeuroPharma’s evolution into a commercial-stage organization. Len and Jerry bring a wealth of commercial strategy and product launch experience in competitive and complex markets, including operationalizing field and managed care teams, market access analytics and formulary negotiations, and product distribution and supply chain management. Collectively, these attributes make them ideal candidates to help the company as we advance our go-to-market strategy for Trudhesa in acute migraine and continue to progress our other clinical development programs in the acute treatment of agitation and aggression in patients with autism and in Parkinson’s disease.”
Read the Impel Neuropharma press release.
